about
The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infectionsInfluence of physical properties of carrier on the performance of dry powder inhalersAn overview of clinical and commercial impact of drug delivery systemsPoly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteinsCharacterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalersEffect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.Oxidation increases mucin polymer cross-links to stiffen airway mucus gelsDry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agentEffect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers.Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction.Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken designEffect of compression pressure on inhalation grade lactose as carrier for dry powder inhalations.Development of Biodegradable Polycation-Based Inhalable Dry Gene Powders by Spray Freeze DryingLevofloxacin-proliposomes: opportunities for use in lung tuberculosis.In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.Advances in metered dose inhaler technology: formulation developmentDevices for dry powder drug delivery to the lung.Inhalable lactose-based dry powder formulations of low molecular weight heparin.Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunitiesCombination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.Evaluation of cariogenic potential of dry powder inhalers: A case-control study.Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study.Nanosized rods agglomerates as a new approach for formulation of a dry powder inhalerEffect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.Chapter 9 - Nanoliposomal dry powder formulations.Effects of device and formulation on in vitro performance of dry powder inhalers.
P2860
Q21131311-DC2E5AAB-FE94-43C3-94DE-0626D96EBEABQ26740570-E9F976EE-79AC-4F14-90AD-49BAF78790DDQ27007143-118A74EE-80DA-427F-90EE-5E419675C7CAQ30371205-F0BC7A51-8339-4873-AF3F-0D91AC893C2EQ30498062-B168DFF4-F34C-44DE-8BD2-055A3E28BFB4Q30525704-89D31F20-D08C-4F6C-978F-ACDD191EDEE8Q30641502-EA2537DB-04FD-4376-8833-D3ABE144230AQ33811796-7C6F3CA3-9E20-42E2-B889-7E9210AAB32FQ34496228-ED926CBE-C5D8-4CA8-9D54-5BDEC0B615C1Q34597067-61BEF2EF-8CB6-42C2-A187-B4C1CF98A44CQ35205790-80B2B249-7474-4EE9-8BED-CDBA3DE3810CQ35796474-2204D8A7-EF93-4DED-A092-89F0FD58CF5EQ35970149-3F82D750-76EA-4320-A8DC-C2CDB3176150Q36105834-0767D36E-5D4D-42D8-959C-28BAE82EFD06Q37327834-50C39CF9-FD33-4FB7-9DAB-9EA86B74CA57Q37507766-8D15A6D5-1188-48A1-AB2A-1BA8145CCCBDQ38180975-A693AEA9-CA54-4F85-960B-9015D25D7D33Q38474246-D5D238F7-017C-40BD-B8C8-86C6AEE2284DQ38742278-4A607F92-5D3A-42D6-A1AF-01BAF8D0DA93Q39306543-8B55BF6E-C53E-4DA6-9825-E01C38AC7CD1Q39856908-58D75EB5-0AAD-44CE-8533-9C98B4A77FC4Q39897715-C1F04F4B-6D1C-48F6-8305-ED4AAD8B360AQ41345764-CD044CB7-8A55-4CBA-B046-DEF0F7AD803CQ41498114-4EC7552C-B721-4083-8DC9-356915BE60EFQ41845309-4A67B5C7-1F89-4B8C-93D1-7D14D064CD86Q41984406-7609029F-50A4-48E4-AF9D-878C88B9DAEAQ41987785-8BC26982-572B-4DB8-AEFA-A39C5AF3FB09Q42097420-A4FB2F5C-B675-41AB-9D01-C65C81FED749Q42218975-AD0E2BDE-E830-471D-87E4-3219193C40AB
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Dry powder inhaler formulation.
@ast
Dry powder inhaler formulation.
@en
type
label
Dry powder inhaler formulation.
@ast
Dry powder inhaler formulation.
@en
prefLabel
Dry powder inhaler formulation.
@ast
Dry powder inhaler formulation.
@en
P1433
P1476
Dry powder inhaler formulation
@en
P2093
Anthony J Hickey
Martin J Telko
P304
P577
2005-09-01T00:00:00Z